Wound Healing Modulation in Glaucoma Filtering Surgery

International Ophthalmology Clinics

Volumn 44, Issue 2, 2004, Pages 61-106

  Atreides, Sean Paul A ^a   Skuta, Gregory L ^a   Reynolds, Adam C ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINOPROPIONITRILE; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; BETA INTERFERON; BRIMONIDINE; CORTICOSTEROID; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; FIBRINOLYTIC AGENT; FLUOROURACIL; GAMMA INTERFERON; GENISTEIN; LATANOPROST; LERDELIMUMAB; METALLOPROTEINASE INHIBITOR; MITOMYCIN C; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN P21; SURAMIN; TRANILAST; TRANSFORMING GROWTH FACTOR BETA ANTIBODY;

AGE DISTRIBUTION; ANGIOGENESIS; ANTERIOR EYE SEGMENT; APHAKIA; BLOOD CLOTTING; CLINICAL TRIAL; COLLAGEN SYNTHESIS; CORTICOSTEROID THERAPY; ELECTRON THERAPY; FIBROBLAST; GLAUCOMA; GLAUCOMA SURGERY; GRANULATION TISSUE; HEMOSTASIS; HUMAN; INFLAMMATORY INFILTRATE; NEUTROPHIL CHEMOTAXIS; PHOTODYNAMIC THERAPY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PSEUDOPHAKIA; RACE DIFFERENCE; RETINA MACULOPATHY; RETINA NEOVASCULARIZATION; REVIEW; SECONDARY GLAUCOMA; SIDE EFFECT; SURGICAL TECHNIQUE; THROMBOCYTE AGGREGATION; UVEITIS; WOUND HEALING;

FILTERING SURGERY; GLAUCOMA; HUMANS; WOUND HEALING;

EID: 1942502216     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004397-200404420-00007     Document Type: Review

References (327)

1. Quigley H. Number of people with glaucoma worldwide. Br J Ophthalmol. 1996;80:389-393.
2. Thylefors B, Negrel A. The global impact of glaucoma. Bull World Health Org. 1994;72:323-326.
3. Foster A, Johnson G. Magnitude and causes of blindness in the developing world. Int Ophthalmol. 1990;14:135-140.
4. Basic and Clinical Sciences Course. Section 10, Glaucoma. San Francisco, CA: American Academy of Ophthalmology; 2001-2002.
5. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: Baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:714-720.
6. Stamper R, Lieberman M, Drake M. Becker-Shaffer's: Diagnosis and Therapy of the Glaucomas. 7th ed. St. Louis, MO: 1999.
7. Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108:1943-1953.
8. Feiner L, Plitz-Seymour JR. Collaborative Initial Glaucoma Treatment Study: A summary of results to date. Curr Opin Ophthalmol. 2003;14:106-111.
9. Migdal C, Gregory W, Hitchings R. Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology. 1994;101:1651-1656.
10. Jay J. Rational choice of therapy in primary open angle glaucoma. Eye. 1992;6:243-247.
11. deWecker L. La cicatrice a filtration. Ann Oculist. 1882;87:133-143.
12. Skuta GL. Antifibrotic agents in glaucoma filtering surgery. Intl Ophthalmol Clin. 1993;33:165-182.
13. Tahery MM, Lee DA. Review: pharmacologic control of wound healing in glaucoma filtration surgery. J Ocul Pharmacol. 1989;5:155-179.
14. Clark R, Henson P. The Molecular and Cellular Biology of Wound Repair. New York, NY: Plenum Press; 1988.
15. Singer A, Clark R. Cutaneous wound healing. N Engl J Med. 1999;341:738-746.
16. Desjardins DC, Parrish RK II, Folberg R, et al. Wound healing after filtering surgery in owl monkeys. Arch Ophthalmol. 1986;104:1835-1839.
17. Skuta GL, Parrish RK II. Wound healing in glaucoma filtering surgery. Surv Ophthalmol. 1987;32:149-170.
18. Dvorak HF. Tumors: wounds that do not heal; similarities between tumor stroma generation and wound healing. N Engl J Med. 1986;315:1650-1659.
19. Albert DM, Jakobiec FA. New surgical techniques in glaucoma management. In: Principles and Practice of Ophthalmology. 2nd ed. Philadelphia, PA: W.B. Saunders; 2000:3024-3030.
20. Seetner A, Morin JD. Healing of trabeculectomies in rabbits. Can J Ophthalmol. 1979;14:121-125.
21. Goodman DF, Alvarado JA, Stern W, et al. Liposomal incorporated 5-fluoroorotate inhibition of wound healing following posterior lip sclerectomy in the primate. Invest Ophthalmol Vis Sci. 1987;28:271.
22. Cordeiro MF, Chang L, Lim KS, et al. Modulating conjunctival wound healing. Eye 2000;14:536-547.
23. Daniels JT, Cambrey AD, Occleston NL, et al. Matrix metalloproteinase inhibition modulates fibroblast-mediated matrix contraction and collagen production in vitro. Invest Ophthalmol Vis Sci. 2003;44:1104-1110.
24. Addicks EM, Quigley HA, Green WR, et al. Histologic characteristics of filtering blebs in glaucomatous eyes. Arch Ophthalmol. 1983;101:795-798.
25. Jampel HD, McGuigan LJ, Dunkelberger GR. Cellular proliferation after experimental glaucoma filtering surgery. Arch Ophthalmol. 1988;106:89-94.
26. Broadway DC, Grierson I, O'Brien C, et al. Adverse effects of topical antiglaucoma medications. I. The conjunctival cell profile. Arch Ophthalmol. 1994;112:1437-1445.
27. Broadway DC, Grierson I, O'Brien C, et al. Adverse effects of topical antiglaucoma medications II. The outcome of filtration surgery. Arch Ophthalmol. 1994;112:1446-1454.
28. Baun O, Heegaard S, Kessing SV, et al. The morphology of conjunctiva after long-term topical anti-glaucoma treatment. A quantitative analysis. Acta Ophthalmol Scand. 1995;73:242-245.
29. Smith DL, Skuta GL, Kincaid MC, et al. The effects of glaucoma medications on Tenon's capsule and conjunctiva in the rabbit. Ophthalmic Surg. 1991;22:336-340.
30. Lark KK, Pasha AS, Yan X, et al. The effect of latanaprost and brimonidine on rabbit subconjunctival fibroblasts. J Glaucoma. 1999;8:72-76.
31. Baudouin C, Pisella PJ, Fillacier K, et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Ophthalmology. 1999;106:556-563.
32. Nuzzi R, Finazzo C, Cerruti A. Adverse effects of topical antiglaucomatous medications on the conjunctiva and the lachrymal response. Int Ophthalmol. 1998;22:31-35.
33. Becquet F, Goldschild M, Moldovan MS, et al. Histopathological effects of topical ophthalmic preservatives on rat corneoconjunctival surface. Curr Eye Res. 1998;17:419-425.
34. Turacli E, Budak K, Kaur A, et al. The effects of long-term topical glaucoma medication on conjunctival impression cytology. Int Ophthalmol. 1997;21:27-33.
35. Cvenkel B, Ihan A. Ocular surface changes induced by topical antiglaucoma monotherapy. Ophthalmologica. 2002;216:175-179.
36. Costagliola C, Prete AD, Incorvaia C, et al. Ocular surface changes induced by topical application of latanoprost and timolol: A short-term study in glaucomatous patients with and without allergic conjunctivitis. Graefes Arch Clin Exp Ophthalmol. 2001;239:809-814.
37. Mietz H, Niesen U, Krieglstein GK. The effect of preservatives and antiglaucomatous medication on the histopathology of the conjunctiva. Graefes Arch Clin Exp Ophthalmol. 1994;232:561-565.
38. Broadway DC, Grierson I, Sturmer J, et al. Reversal of topical antiglaucoma medication effects on the conjunctiva. Arch Ophthalmol. 1996;114:262-267.
39. Baudouin C, Nordmann JP, Denis P, et al. Efficacy of indomethacin 0.1% and fluorometholone 0.1% on conjunctival inflammation following chronic application of antiglaucomatous drugs. Graefes Arch Clin Exp Ophthalmol. 2002;240:929-935.
40. Miller RD, Barber JC. Trabeculectomy in black patients. Ophthalmic Surg. 1981;12:46-50.
41. Berson D, Zauberman H, Landau L, et al. Filtering operations in Africans. Am J Ophthalmol. 1969;67:395-398.
42. Iliff CE. Surgical control of glaucoma in the negro. Am J Ophthalmol. 1944;27:731-738.
43. Scott IU, Greenfield DS, Schiffman J, et al. Outcomes of primary trabeculectomy with the use of adjunctive mitomycin. Arch Ophthalmol. 1998;116:286-291.
44. Shin DH, Hughes BA, Song MS, et al. Primary glaucoma triple procedure with or without adjunctive mitomycin. Prognostic factors for filtration failure. Ophthalmology. 1996;103:1925-1933.
45. Merritt JC. Filtering procedures in American blacks. Ophthalmic Surg. 1980;11:91-94.
46. Shields MB. Textbook of Glaucoma. 4th ed. Baltimore, MD: Williams & Wilkins; 1998:513.
47. McMillan TA, Stewart WC, Hennis HL, et al. Histologic differences in the conjunctiva of black and white glaucoma patients. Ophthalmic Surg. 1992;23:762-765.
48. Broadway D, Grierson I, Hitchings R. Racial differences in the results of glaucoma filtration surgery: Are racial differences in the conjunctival cell profile important? Br J Ophthalmol. 1994;78:466-475.
49. Mwanza JC, Kabasele PM. Trabeculectomy with and without mitomycin-C in a black African population. Eur J Ophthalmol. 2001;11:261-263.
50. Singh K, Egbert PR, Byrd S, et al. Trabeculectomy with intraoperative 5-fluorouracil vs mitomycin C. Am J Ophthalmol. 1997;123:48-53.
51. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 11. Risk factors for failure of trabeculectomy and argon laser trabeculoplasty. Am J Ophthalmol. 2002;134:481-498.
52. The Fluorouracil Filtering Surgery Study Group. Five-year follow-up of the Fluorouracil Filtering Surgery Study. Am J Ophthalmol. 1996;121:349-366.
53. Beauchamp GR, Parks MM. Filtering surgery in children: barriers to success. Ophthalmology. 1979;86:170-180.
54. Cadera W, Pachtman MA, Cantor LB, et al. Filtering surgery in childhood glaucoma. Ophthalmic Surg. 1984;15:319-322.
55. Gressel MG, Heuer DK, Parrish RK II. Trabeculectomy in young patients. Ophthalmology. 1984;91:1242-1246.
56. Sturmer J, Broadway DC, Hitchings RA. Young patient trabeculectomy. Assessment of risk factors for failure. Ophthalmology. 1993;100:928-939.
57. Jacobi PC, Dietlein TS, Krieglstein GK. Primary trabeculectomy in young adults: Long-term clinical results and factors influencing the outcome. Ophthalmic Surg Lasers. 1999;30:637-646.
58. Costa VP, Katz LJ, Spaeth GL, et al. Primary trabeculectomy in young adults. Ophthalmology. 1993;100:1071-1076.
59. Zalish M, Leiba H, Oliver M. Subconjunctival injection of 5-fluorouracil following trabeculectomy for congenital and infantile glaucoma. Ophthalmic Surg. 1992;23:203-205.
60. Whiteside-Michel J, Liebmann JM, Ritch R. Initial 5-fluorouracil trabeculectomy in young patients. Ophthalmology. 1992;99:7-13.
61. Yalvac IS, Nurozler A, Kahraman C, et al. The results of trabeculectomy with and without mitomycin C in young patients. Ophthalmologica. 1998;212:399-403.
62. Mandal AK, Prasad K, Naduvilath TJ. Surgical results and complications of mitomycin C-augmented trabeculectomy in refractory developmental glaucoma. Ophthalmic Surg Lasers. 1999;30:473-480.
63. Miller MH, Rice NS. Trabeculectomy combined with beta irradiation for congenital glaucoma. Br J Ophthalmol. 1991;75:584-590.
64. Kok H, Barton K. Uveitic glaucoma. Ophthalmol Clin North Am. 2002;15:375-387.
65. Broadway DC, Chang LP. Trabeculectomy, risk factors for failure and the preoperative state of the conjunctiva. J Glaucoma. 2001;10:237-249.
66. Hill RA, Nguyen QH, Baerveldt G, et al. Trabeculectomy and Molteno implantation for glaucomas associated with uveitis. Ophthalmology. 1993;100:903-908.
67. Stavrou P, Murray PI. Long-term follow-up of trabeculectomy without antimetabolites in patients with uveitis. Am J Ophthalmol. 1999;128:434-439.
68. Towler HM, McCluskey P, Shaer B, et al. Long-term follow-up of trabeculectomy with intraoperative 5-fluorouracil for uveitis-related glaucoma. Ophthalmology. 2000;107:1822-1828.
69. Jampel HD, Jabs DA, Quigley HA. Trabeculectomy with 5-fluorouracil for adult inflammatory glaucoma. Am J Ophthalmol. 1990;109:168-173.
70. The Fluorouracil Filtering Surgery Study Group. Fluorouracil Filtering Surgery Study one-year follow-up. Am J Ophthalmol. 1989;108:625-635.
71. The Fluorouracil Filtering Surgery Study Group. Three-year follow-up of the Fluorouracil Filtering Surgery Study. Am J Ophthalmol. 1993;115:82-92.
72. Prata JA Jr, Neves RA, Minckler DS, et al. Trabeculectomy with mitomycin C in glaucoma associated with uveitis. Ophthalmic Surg. 1994;25:616-620.
73. Ceballos EM, Beck AD, Lynn MJ. Trabeculectomy with antiproliferative agents in uveitic glaucoma. J Glaucoma. 2002;11:189-196.
74. Sivak-Callcott JA, O'Day DM, Gass JD, et al. Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology. 2001;108:1767-1776.
75. Tripathi RC, Li J, Tripathi BJ, et al. Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology. 1998;105:232-237.
76. Tsai JC, Feuer WJ, Parrish RK II, et al. 5-Fluorouracil filtering surgery and neovascular glaucoma. Long-term follow-up of the original pilot study. Ophthalmology. 1995;102:887-892.
77. Mandal AK, Majji AB, Mandal SP, et al. Mitomycin-C-augmented trabeculectomy for neovascular glaucoma. A preliminary report. Indian J Ophthalmol. 2002;50:287-293.
78. Hyung SM, Kim SK. Mid-term effects of trabeculectomy with mitomycin C in neovascular glaucoma patients. Korean J Ophthalmol. 2001;15:98-106.
79. Bellows AR, Johnstone MA. Surgical management of chronic glaucoma in aphakia. Ophthalmology. 1983;90:807-813.
80. Herschler J, Litinsky SM, Shaffer RN, et al. Surgical treatment of glaucoma in the aphakic patient. In: Emery JM, ed. Current Concepts in Cataract Surgery; Selected Proceedings of the Fifth Biennial Cataract Surgical Congress. St Louis, MO: CV Mosby; 1978:426-428.
81. Herschler J. The effect of total vitrectomy on filtration surgery in the aphakic eye. Ophthalmology. 1981;88:229-232.
82. Heuer DK, Gressel MG, Parrish RK II, et al. Trabeculectomy in aphakic eyes. Ophthalmology. 1984;91:1045-1051.
83. Mehta KR, Sathe SN, Karyekar SD. Trabeculectomy ab-externo. Indian J Ophthalmol. 1974;22:9-12.
84. Schwartz AL, Anderson DR. Trabecular surgery. Arch Ophthalmol. 1974;92:134-138.
85. Sharma SL, Singh T. Clinical evaluation of trabeculectomy operation in aphakic glaucoma. Indian J Ophthalmol. 1981;29:227-228.
86. Singh D, Singh M. Pretrabecular filtration in aphakic glaucoma. Indian J Ophthalmol. 1978;26:17-21.
87. Maumenee AE. External filtering operations for glaucoma: The mechanism of function and failure. Trans Am Ophthalmol Soc. 1960;58:319-328.
88. Maumenee AE. Mechanism of filtration of fistulizing glaucoma procedures. In: Symposium on Glaucoma, Transactions of the New Orleans Academy of Ophthalmology. St Louis, MO: CV Mosby Co; 1981:280-288.
89. Deleted in proof
90. Deleted in proof
91. Verdoorn C, Miller B, Miller H, et al. The role of growth factors in proliferative vitreoretinopathy. ARVO Abstracts. Invest Ophthalmol Vis Sci. 1985;26:23.
92. Wiedemann P, Ryan SJ, Novak P, et al. Vitreous stimulates proliferation of fibroblasts and retinal pigment epithelial cells. Exp Eye Res. 1985;41:619-628.
93. Lamping KA, Belkin JK. 5-Fluorouracil and mitomycin C in pseudophakic patients. Ophthalmology. 1995;102:70-75.
94. Falck FY Jr, Skuta GL, Klein TB. Mitomycin versus 5-fluorouracil antimetabolite therapy for glaucoma filtering surgery. Semin Ophthalmol. 1992;7:97-109.
95. Chang L, Crowston JG, Cordeiro MF, et al. The role of the immune system in conjunctival wound healing after glaucoma surgery. Surv Ophthalmol. 2000;45:49-68.
96. Abelson MB, Butrus S, Albert DM. Corticosteroids in ophthalmic practice. In: Principles and Practice of Ophthalmology. 2nd ed. Albert DM, Jakobiec FA, eds. Philadelphia, PA: W.B. Saunders; 2000:258-267.
97. Lama PJ, Fechtner RD. Antifibrotics and wound healing in glaucoma surgery. Surv Ophthalmol. 2003;48:314-346.
98. Starita RJ, Fellman RL, Spaeth GL, et al. Short- and long-term effects of postoperative corticosteroids on trabeculectomy. Ophthalmology. 1985;92:938-946.
99. Roth SM, Spaeth GL, Starita RJ, et al. The effects of postoperative corticosteroids on trabeculectomy and the clinical course of glaucoma: five-year follow-up study. Ophthalmic Surg. 1991;22:724-729.
100. Araujo SV, Spaeth GL, Roth SM, et al. A ten-year follow-up on a prospective, randomized trial of postoperative corticosteroids after trabeculectomy. Ophthalmology. 1995;102:1753-1759.
101. Nguyen KD, Lee DA. Effect of steroids and nonsteroidal anti-inflammatory agents on human ocular fibroblasts. Invest Ophthalmol Vis Sci. 1992;33:2693-2701.
102. Gwin TD, Stewart WC, Gwynn DR. Filtration surgery in rabbits treated with diclofenac or prednisolone acetate. Ophthalmic Surg. 1994;25:245-250.
103. Kraff MC, Sanders DR, McGuigan L, et al. Inhibition of blood-aqueous humor barrier breakdown with diclofenac. A fluorophotometric study. Arch Ophthalmol. 1990;108:380-383.
104. Roberts CW. Pretreatment with topical diclofenac sodium to decrease postoperative inflammation. Ophthalmology. 1996;103:636-639.
105. Kent AR, Dubiner HB, Whitaker R, et al. The efficacy and safety of diclofenac 0.1% versus prednisolone acetate 1% following trabeculectomy with adjunctive mitomycin-C. Ophthalmic Surg Lasers. 1998;29:562-569.
106. Simmons RJ. Filtering operations. In: Epstein DL, ed. Chandler and Grant's Glaucoma. Philadelphia, PA: Lea and Febiger; 1986:421,427,447.
107. Friedenwald JS. Some problems in the diagnosis and treatment of glaucoma. Am J Ophthalmol. 1950;33:1523-1538.
108. Haynes WL, Alward WL. Combination of autologous blood injection and bleb compression sutures to treat hypotony maculopathy. J Glaucoma. 1999;8:384-387.
109. Wise JB. Treatment of chronic postfiltration hypotony by intrableb injection of autologous blood. Arch Ophthalmol. 1993;11:827-830.
110. Smith MF, Magauran RG 3rd, Betchkal J, et al. Treatment of postfiltration bleb leaks with autologous blood. Ophthalmology. 1995;102:868-871.
111. Leen MM, Moster MR, Katz LJ, et al. Management of overfiltering and leaking blebs with autologous blood injection. Arch Ophthalmol. 1995;113:1050-1055.
112. Costa VP, Spaeth GL, Eiferman RA, et al. Wound healing modulation in glaucoma filtration surgery. Ophthalmic Surg. 1993;24:152-170.
113. Slack JW, Hyndiuk RA. Toxicology of surgical solutions and drugs. In: Principles and Practice of Ophthalmology. 2nd ed. Albert DM, Jakobiec FA, eds. Philadelphia, PA: W.B. Saunders; 2000:483-484.
114. Snyder RW, Lambrou FH, Williams GA. Intraocular fibrinolysis with recombinant human tissue plasminogen activator. Experimental treatment in a rabbit model. Arch Ophthalmol. 1987;105:1277-1280.
115. Strauss GH, Dunn ET, Dunn RC, et al. Subconjunctival high dose plasminogen activator in rabbit filtration surgery. J Ocul Pharmacol. 1991;7:9-19.
116. Fourman S, Wiley L. Tissue plasminogen activator modifies healing of glaucoma filtering surgery in rabbits. Ophthalmic Surg. 1991;22:718-723.
117. Fourman S, Vaid K. Effects of tissue plasminogen activator on glaucoma filter blebs in rabbits. Ophthalmic Surg. 1989;20:663-667.
118. Georgiadis N, Boboridis K, Halvatzis N, et al. Low-dose tissue plasminogen activator in the management of anterior chamber fibrin formation. J Cataract Refract Surg. 2003;29:729-732.
119. Wedrich A, Menapace R, Ries E, et al. Intracameral tissue plasminogen activator to treat severe fibrinous effusion after cataract surgery. J Cataract Refract Surg. 1997;23:873-877.
120. Moon J, Chung S, Myong Y, et al. Treatment of postcataract fibrinous membranes with tissue plasminogen activator. Ophthalmology. 1992;99:1256-1259.
121. Wedrich A, Menapace R, Muhlbauer-Ries E. The use of recombinant tissue plasminogen activator for intracameral fibrinolysis following cataract surgery. Int Ophthalmol. 1994-95;18:277-280.
122. Heiligenhaus A, Steinmetz B, Lapuente R, et al. Recombinant tissue plasminogen activator in cases with fibrin formation after cataract surgery: A prospective randomised multicentre study. Br J Ophthalmol. 1998;82:810-815.
123. Lundy DC, Sidoti P, Winarko T, et al. Intracameral tissue plasminogen activator after glaucoma surgery. Indications, effectiveness, and complications. Ophthalmology. 1996;103:274-282.
124. Smith MF, Doyle JW. Use of tissue plasminogen activator to revive blebs following intraocular surgery. Arch Ophthalmol. 2001;119:809-812.
125. Lee PF, Myers KS, Hsieh MM, et al. Treatment of failing glaucoma filtering cystic blebs with tissue plasminogen activator (tPA). J Ocul Pharmacol Ther. 1995;11:227-232.
126. Piltz JR, Starita RJ. The use of subconjunctivally administered tissue plasminogen activator after trabeculectomy. Ophthalmic Surg. 1994;25:51-53.
127. Zwaan J, Latimer WB. Topical tissue plasminogen activator appears ineffective for the clearance of intraocular fibrin. Ophthalmic Surg Lasers. 1998;29:476-483.
128. Iverson DA, Katsura H, Hartzer MK, et al. Inhibition of intraocular fibrin formation following infusion of low-molecular-weight heparin during vitrectomy. Arch Ophthalmol. 1991;109:405-409.
129. Kruger A, Amon M, Abela-Formanek C, et al. Effect of heparin in the irrigation solution on postoperative inflammation and cellular reaction on the intraocular lens surface. J Cataract Refract Surg. 2002;28:87-92.
130. Kohen T, Dick B, Hessemer V, et al. Effect of heparin in irrigating solution on inflammation following small incision cataract surgery. J Cataract Refract Surg. 1998;24:237-243.
131. Asaria RH, Kon CH, Bunce C, et al. Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: Results from a randomized, double-blind, controlled clinical trial. Ophthalmology. 2001;108:1179-1183.
132. Joseph JP, Grierson I, Hitchings RA. Taxol, cytochalasin B and colchicine effects on fibroblast migration and contraction: A role in glaucoma filtration surgery? Curr Eye Res. 1989;8:203-215.
133. Jampel HD, Koya P, Leong K, et al. In vitro release of hydrophobic drugs from polyanhydride disks. Ophthalmic Surg. 1991;22:676-680.
134. Jampel HD, Thibault D, Leong KW, et al. Glaucoma filtration surgery in nonhuman primates using taxol and etoposide in polyanhydride carriers. Invest Ophthalmol Vis Sci. 1993;34:3076-3083.
135. Jampel HD, Moon JI. The effect of paclitaxel powder on glaucoma filtration surgery in rabbits. J Glaucoma. 1998;7:170-177.
136. Pastor JC, Rodriguez E, Marcos MA, et al. Combined pharmacologic therapy in a rabbit model of proliferative vitreoretinopathy (PVR). Ophthalmic Res. 2000;32:25-29.
137. Heuer DK, Parrish RK II, Gressel MG, et al. 5-Fluorouracil and glaucoma filtering surgery: II. A pilot study. Ophthalmology. 1984;91:384-393.
138. Heuer DK, Parrish RK II, Gressel MG, et al. 5-Fluorouracil and glaucoma filtering surgery: III. Intermediate follow-up of a pilot study. Ophthalmology. 1986;93:1537-1546.
139. Rockwood EJ, Parrish RK II, Heuer DK, et al. Glaucoma filtering surgery with 5-fluorouracil. Ophthalmology. 1987;94:1071-1078.
140. Ruderman SM, Welch DB, Smith MF, et al. A randomized study of 5-fluorouracil and filtration surgery. Am J Ophthalmol. 1987;104:218-224.
141. Weinreb RN. Adjusting the dose of 5-fluorouracil after filtration surgery to minimize side effects. Ophthalmology. 1987;94:564-570.
142. Liebmann JM, Ritch R, Marmor M, et al. Initial 5-fluorouracil trabeculectomy in uncomplicated glaucoma. Ophthalmology. 1991;98:1036-1041.
143. Ophir A, Ticho U. A randomized study of trabeculectomy and subconjunctival administration of fluorouracil in primary glaucomas. Arch Ophthalmol. 1992;110:1072-1075.
144. Wilson RP, Steinmann WL. Use of trabeculectomy with postoperative 5-fluorouracil in patients requiring extremely low intraocular pressure levels to limit further glaucomatous progression. Ophthalmology. 1991;98:1047-1052.
145. Blumenkranz MS, Ophir A, Claflin AJ, et al. Fluorouracil for the treatment of massive periretinal proliferation. Am J Ophthalmol. 1982;94:458-467.
146. Davis-Lemessy PA, Parrish RK II. Antimetabolites for trabeculectomy: 5-FU and mitomycin C. In: Principles and Practice of Ophthalmology. 2nd ed. Albert DM, Jakobiec FA, eds. Philadelphia, PA: W.B. Saunders; 2000:354-357.
147. Daniels JT, Occleston NL, Crowston JG, et al. Effects of antimetabolite induced cellular growth arrest on fibroblast-fibroblast interactions. Exp Eye Res. 1999;69:117-127.
148. Jampel HD. Effect of brief exposure to mitomycin C on viability and proliferation of cultured human Tenon's capsule fibroblasts. Ophthalmology. 1992;99:1471-1476.
149. Khaw PT, Sherwood MB, MacKay SL, et al. Five-minute treatments with fluorouracil, floxuridine, and mitomycin have long-term effects on human Tenon's capsule fibroblasts. Arch Ophthalmol. 1992;110:1150-1154.
150. Gressel MG, Parrish RK II, Folberg R. 5-Fluorouracil and glaucoma filtering surgery: I. An animal model. Ophthalmology. 1984;91:378-383.
151. Khaw PT, Doyle JW, Sherwood MB, et al. Effects of intraoperative 5-fluorouracil or mitomycin C on glaucoma filtration surgery in the rabbit. Ophthalmology. 1993;100:367-372.
152. Rothman RF, Liebmann JM, Ritch R. Low-dose 5-fluorouracil trabeculectomy as initial surgery in uncomplicated glaucoma: Long-term follow-up. Ophthalmology. 2000;107:1184-1190.
153. Goldenfeld M, Krupin T, Ruderman JM, et al. 5-Fluorouracil in initial trabeculectomy: a prospective, randomized, multi-center study. Ophthalmology. 1994;101:1024-1029.
154. Ruderman JM, Welch DB, Smith MF, et al. A randomized study of 5-fluorouracil and filtration surgery. Am J Ophthalmol. 1987;104:218-224.
155. Leyland M, Bloom P, Zinicola E, et al. Single intraoperative application of 5-fluorouracil versus placebo in low-risk trabeculectomy surgery: A randomized trial. J Glaucoma. 2001;10:452-457.
156. Chaudhry IA, Pasha MA, O'Connor DJ, et al. Randomized, controlled study of low-dose 5-fluorouracil in primary trabeculectomy. Am J Ophthalmol. 2000;130:700-703.
157. Uchida S, Suzuki Y, Araie M, et al. Long-term follow-up of initial 5-fluorouracil trabeculectomy in primary open-angle glaucoma in Japanese patients. J Glaucoma. 2001;10:458-465.
158. Wong JS, Yip L, Tan C, et al. Trabeculectomy survival with and without intra-operative 5-fluorouracil application in an Asian population. Aust N Z J Ophthalmol, 1998;26:283-288.
159. Lamba PA, Pandey PK, Raina UK, et al. Short-term results of initial trabeculectomy with intraoperative or postoperative 5-fluorouracil for primary glaucomas. Indian J Ophthalmol. 1997;45:173-176.
160. Egbert PR, Williams AS, Singh K, et al. A prospective trial of intraoperative fluorouracil during trabeculectomy in a black population. Am J Ophthalmol. 1993;116:612-616.
161. Membrey WL, Bunce C, Poinoosawmy DP, et al. Glaucoma surgery with or without adjunctive antiproliferatives in normal tension glaucoma: 2 Visual field progression. Br J Ophthalmol. 2001;85:696-701.
162. Rockwood EJ, Larive B, Hahn J. Outcomes of combined cataract extraction, lens implantation, and trabeculectomy surgeries. Am J Ophthalmol. 2000;130:704-711.
163. Ren J, Shin DH, O'Grady JM, et al. Long-term outcome of primary glaucoma triple procedure with adjunctive 5-fluorouracil. Graefes Arch Clin Exp Ophthalmol. 1998;236:501-506.
164. Singh RP, Goldberg I, Mohsin M. The efficacy and safety of intraoperative and/or postoperative 5-fluorouracil in trabeculectomy and phacotrabeculectomy. Clin Experiment Ophthalmol. 2001;29:296-302.
165. Jampel HD, Friedman DS, Lubomski LH, et al. Effect of technique on intraocular pressure after combined cataract and glaucoma surgery: An evidence-based review. Ophthalmology. 2002;109:2215-2224.
166. Kitazawa Y, Kawase K, Matsushita H, et al. Trabeculectomy with mitomycin: A comparative study with fluorouracil. Arch Ophthalmol. 1991;109:1693-1698.
167. Skuta GL, Beeson CC, Higginbotham EJ, et al. Intraoperative mitomycin versus postoperative 5-fluorouracil in high-risk glaucoma filtering surgery. Ophthalmology. 1992;99:438-444.
168. Durak I, Ozbek Z, Yaman A, et al. The role of needle revision and 5-fluorouracil application over the filtration site in the management of bleb failure after trabeculectomy: A prospective study. Doc Ophthalmol. 2003;106:189-193.
169. Ophir A, Wasserman D. 5-Fluorouracil-needling and paracentesis through the failing filtering bleb. Ophthalmic Surg Lasers. 2002;33:109-116.
170. Hawkins AS, Flanagan JK, Brown SV. Predictors for success of needle revision of failing filtration blebs. Ophthalmology. 2002;109:781-785.
171. Chalfin S, Memmen JE. Corneal endothelial toxic effect secondary to fluorouracil needle bleb revision. Arch Ophthalmol. 1995;113:1093-1094.
172. Levkovitch-Verbin H, Goldenfeld M, Melmed S. Fornix-based trabeculectomy with mitomycin-C. Ophthalmic Surg Lasers. 1997;28:818-822.
173. Wise JB. Mitomycin-compatible suture technique for fornix-based conjunctival flaps in glaucoma filtration surgery. Arch Ophthalmol. 1993;111:992-997.
174. Miller KN, Blasini M, Shields MB, et al. A comparison of total and partial tenonectomy with trabeculectomy. Am J Ophthalmol. 1991;111:323-326.
175. Smith MF, Doyle JW, Nguyen QH, et al. Results of intraoperative 5-fluorouracil or lower dose mitomycin-C administration on initial trabeculectomy surgery. J Glaucoma. 1997;6:104-110.
176. Raina UK, Tuli D. Trabeculectomy with releasable sutures: A prospective, randomized pilot study. Arch Ophthalmol. 1998;116:1288-1293.
177. Tezel G, Kolker AE, Kass MA, et al. Late removal of releasable sutures after trabeculectomy or combined trabeculectomy with cataract extraction supplemented with antifibrotics. J Glaucoma. 1998;7:75-81.
178. Maberley D, Apel A, Rootman DS. Releasable "U" suture for trabeculectomy surgery. Ophthalmic Surg. 1994;25:251-255.
179. Unlu K, Aksunger A, Soker S, et al. Mitomycin C primary trabeculectomy with releasable sutures in primary glaucoma. Jpn J Ophthalmol. 2000;44:524-529.
180. Johnstone MA, Wellington DP, Ziel CJ. A releasable scleral-flap tamponade suture for guarded filtration surgery. Arch Ophthalmol. 1993;111:398-403.
181. Cohen JS, Osher RH. Releasable scleral flap suture. Ophthalmol Clin North Am. 1988;1:187-197.
182. Akimoto M, Miyahara T, Arai J, et al. A new delivery system for 5-fluorouracil using prodrug and converting enzyme. Br J Ophthalmol. 2002;86:581-586.
183. Chiang CH, Tung SM, Lu DW, et al. In vitro and in vivo evaluation of an ocular delivery system of 5-fluorouracil microspheres. J Ocul Pharmacol Ther. 2001;17:545-553.
184. Lu DW, Chang CJ, Chiang CH, et al. Wound modulation after trabeculectomy by different formulations of antimetabolites in rabbits. J Ocul Pharmacol Ther. 2000;16:529-538.
185. Einmahl S, Behar-Cohen F, D'Hermies F, et al. A new poly(ortho ester)-based drug delivery system as an adjunct treatment in filtering surgery. Invest Ophthalmol Vis Sci. 2001;42:695-700.
186. Yamamoto T, Varani J, Soong HK, et al. Effects of 5-fluorouracil and mitomycin-C on cultured rabbit subconjunctival fibroblasts. Ophthalmology. 1990;97:1204-1210.
187. Bergstrom TJ, Wilkinson WS, Skuta GL, et al. The effects of subconjunctival mitomycin-C on glaucoma filtering surgery in rabbits. Arch Ophthalmol. 1991;109:1725-1730.
188. Pasquale LR, Thibault D, Dorman ME, et al. Effects of topical mitomycin-C on glaucoma filtration surgery in monkeys. Ophthalmology. 1992;99:14-18.
189. Derick RJ, Pasquale L, Quigley HA, et al. Potential toxicity of mitomycin-C. Arch Ophthalmol. 1991;109:1635.
190. Assalian A, Scroggs MW, Shields MB, et al. Histology of conjunctival vascular endothelium after filtering surgery with mitomycin C in rabbits. Can J Ophthalmol. 1996;31:289-295.
191. Heaps RS, Nordlund JR, Gonzalez-Fernandez F, et al. Ultrastructural changes in rabbit ciliary body after extraocular mitomycin C. Invest Ophthalmol Vis Sci. 1998;39:1971-1975.
192. Mietz H, Addicks K, Bloch W, et al. Long-term intraocular toxic effects of topical mitomycin C in rabbits. J Glaucoma. 1996;5:325-333.
193. Schraermeyer U, Diestelhorst M, Bieker A, et al. Morphologic proof of the toxicity of mitomycin C on the ciliary body in relation to different application methods. Graefes Arch Clin Exp Ophthalmol. 1999;237:593-600.
194. Teague BJ, Skuta GL, Mardelli PG, et al. Ciliary body and retinal toxicity after subconjunctival injection of mitomycin C in rabbit eyes. Invest Ophthalmol Vis Sci. 1995;36(suppl):S90.
195. Kunimoto N, Mori S. New treatment of pterygium. Acta XIX Concilium Ophthalmologicum; 1962; New Delhi, India: 1099-1105.
196. Chen CW. Enhanced intraocular pressure controlling effectiveness of trabeculectomy by local application of mitomycin-C. Trans Asia-Pacific Acad Ophthalmology. 1983;9:172-177.
197. Chen CW, Huang HT, Sheu MM. Enhancement of IOP control effect of trabeculectomy by local application of anticancer drug. Acta XIX Concilium Ophthalmologicum; 1986; Rome, Italy: 1487-1491.
198. Chen CW, Huang HT, Bair JS, et al. Trabeculectomy with simultaneous topical application of mitomycin C in refractory glaucoma. J Ocular Pharmacol. 1990;6:175-182.
199. Palmer SS. Mitomycin as adjunct chemotherapy with trabeculectomy. Ophthalmology. 1991;98:317-321.
200. Katz GJ, Higginbotham EJ, Lichter PR, et al. Mitomycin C versus 5-fluorouracil in high-risk glaucoma filtering surgery: Extended follow-up. Ophthalmology. 1995;102:1263-1269.
201. Beckers HJ, Kinders KC, Webers CA. Five-year results of trabeculectomy with mitomycin C. Graefes Arch Clin Exp Ophthalmol. 2003;241:106-110.
202. Cheung JC, Wright MM, Murali S, et al. Intermediate-term outcome of variable dose mitomycin C filtering surgery. Ophthalmology. 1997;104:143-149.
203. Perkins TW, Gangnon R, Ladd W, et al. Trabeculectomy with mitomycin C: Intermediate-term results. J Glaucoma. 1998;7:230-236.
204. Bindlish R, Condon GP, Schlosser JD, et al. Efficacy and safety of mitomycin-C in primary trabeculectomy: Five-year follow-up. Ophthalmology. 2002;109:1336-1341.
205. Sanders SP, Cantor LB, Dobler AA, et al. Mitomycin C in higher risk trabeculectomy: A prospective comparison of 0.2 to 0.4 mg/cc doses. J Glaucoma. 1999;8:193-198.
206. Mietz H, Krieglstein GK. Three-year follow-up of trabeculectomies performed with different concentrations of mitomycin-C. Ophthalmic Surg Lasers. 1998;29:628-634.
207. Kim YY, Sexton RM, Shin DH, et al. Outcomes of primary phakic trabeculectomies without versus with 0.5-1-minute versus 3-5-minute mitomycin C. Am J Ophthalmol. 1998;126:755-762.
208. Robin AL, Ramakrishna R, Krishnadus R, et al. A long-term dose-response study of mitomycin in glaucoma filtration surgery. Arch Ophthalmol. 1997;115:969-974.
209. Mietz H, Jacobi PC, Krieglstein GK. Intraoperative episcleral versus postoperative topical application of mitomycin-C for trabeculectomies. Ophthalmology. 2002;109:1343-1349.
210. You YA, Gu YS, Fang CT, et al. Long-term effects of simultaneous subconjunctival and subscleral mitomycin C application in repeat trabeculectomy. J Glaucoma. 2002;11:110-118.
211. El Sayyad F, Belmekki M, Helal M, et al. Simultaneous subconjunctival and subscleral mitomycin-C application in trabeculectomy. Ophthalmology. 2000;107:298-301.
212. Susanna R Jr, Costa VP, Malta RF, et al. Intraoperative mitomycin-C without conjunctival and Tenon's capsule touch in primary trabeculectomy. Ophthalmology. 2001;108:1039-1042.
213. Wilkins MR, Occleston NL, Kotecha A, et al. Sponge delivery variables and tissue levels of 5-fluorouracil. Br J Ophthalmol. 2000;84:92-97.
214. Brincker P, Kessing SV. Limbus-based versus fornix-based conjunctival flap in glaucoma filtering surgery. Acta Ophthalmol. 1992;70:641-644.
215. Reichert R, Stewart W, Shields MB. Limbus-based versus fornix-based conjunctival flaps in trabeculectomy. Ophthalmic Surg. 1987;18:672-676.
216. Shuster JN, Krupin T, Kolker AE, et al. Limbus- v fornix-based conjunctival flap in trabeculectomy. A long-term randomized study. Arch Ophthalmol. 1984;102:361-362.
217. El Sayyad F, el-Rashood A, Helal M, et al. Fornix-based versus limbal-based conjunctival flaps in initial trabeculectomy with postoperative 5-fluorouracil: Four-year follow-up findings. J Glaucoma. 1999;8:124-128.
218. Khaw PT. Antifibrotic therapy: Is there an ideal method of application? Presented at: American Academy of Ophthalmology Annual Meeting - Glaucoma Subspecialty Day Syllabus; 2003; Anaheim, California: 155-159.
219. Wells AP, Cordeiro MF, Bunce C, et al. Cystic bleb formation and related complications in limbus- versus fornix-based conjunctival flaps in pediatric and young adult trabeculectomy with mitomycin C. Ophthalmology. 2003;110:2192-2197.
220. Cordeiro MF, Constable PH, Alexander RA, et al. Effect of varying the mitomycin-C treatment area in glaucoma filtration surgery in the rabbit. Invest Ophthalmol Vis Sci. 1997;38:1639-1646.
221. Greenfield DS, Liebmann JM, Jee J, et al. Late-onset bleb leaks after glaucoma filtering surgery. Arch Ophthalmol. 1998;116:443-447.
222. Higginbotham EJ, Stevens RK, Musch DC, et al. Bleb-related endophthalmitis after trabeculectomy with mitomycin C. Ophthalmology. 1996;103:650-656.
223. Soltau JB, Rothman RF, Budenz DL, et al. Risk factors for glaucoma filtering bleb infections. Arch Ophthalmol. 2000;118:338-342.
224. Jampel HD, Quigley HA, Kerrigan-Baumrind LA, et al. Glaucoma surgical outcomes study group. Risk factors for late-onset infection following glaucoma filtration surgery. Arch Ophthalmol. 2001;119:1001-1008.
225. Stamper RL, McMenemy M, Lieberman MF. Hypotonous maculopathy after trabeculectomy with subconjunctival 5-flurouracil. Am J Ophthalmol. 1992;114:544-553.
226. Fannin LA, Schiffman JC, Budenz DL. Risk factors for hypotony maculopathy. Ophthalmology. 2003;110:1185-1191.
227. Tsai JC, Chang HW, Kao CN, et al. Trabeculectomy with mitomycin C versus trabeculectomy alone for juvenile primary open-angle glaucoma. Ophthalmologica. 2003;217:24-30.
228. Shin DH, Iskander NG, Ahee JA, et al. Long-term filtration and visual field outcomes after primary glaucoma triple procedure with and without mitomycin-C. Ophthalmology. 2002;109:1607-1611.
229. Kozobolis VP, Siganos CS, Christodoulakis EV, et al. Two-site phacotrabeculectomy with intraoperative mitomycin-C: Fornix-versus limbus-based conjunctival opening in fellow eyes. J Cataract Refract Surg. 2002;28:1758-1762.
230. Kleinmann G, Katz H, Pollack A, et al. Comparison of trabeculectomy with mitomycin C with or without phacoemulsification and lens implantation. Ophthalmic Surg Lasers. 2002;33:102-108.
231. Suner IJ, Greenfield DS, Miller MP, et al. Hypotony maculopathy after filtering surgery with mitomycin C. Incidence and treatment. Ophthalmology. 1997;104:207-214.
232. Singh K, Egbert PR, Byrd S, et al. Trabeculectomy with intraoperative 5-fluorouracil vs mitomycin C. Am J Ophthalmol. 1997;123:48-53.
233. Akarsu C, Onol M, Hasanreisoglu B. Postoperative 5-fluorouracil versus intraoperative mitomycin C in high-risk glaucoma filtering surgery: Extended follow up. Clin Experiment Ophthalmol. 2003;31:199-205.
234. Singh K, Mehta K, Shaikh NM, et al. Trabeculectomy with intraoperative mitomycin C versus 5-fluorouracil. Prospective randomized clinical trial. Ophthalmology. 2000;107:2305-2309.
235. WuDunn D, Cantor LB, Palanca-Capistrano AM, et al. A prospective randomized trial comparing intraoperative 5-fluorouracil vs mitomycin C in primary trabeculectomy. Am J Ophthalmol. 2002;134:521-528.
236. Mastropasqua L, Carpineto P, Ciancaglini M, et al. Delayed post-operative use of 5-fluorouracil as an adjunct in medically uncontrolled open angle glaucoma. Eye. 1998;12:701-706.
237. Wee WR, Youn DH. The use of cytosine arabinoside in glaucoma filtering surgery. Korean J Ophthalmol. 1992;6:62-68.
238. Chu JL, Shields SR, Netland PA. Enhancement of filtration surgery with cytosine arabinoside and reversal of toxicity with 2′-deoxycytidine. Curr Eye Res. 1994;13:839-843.
239. Al-Aswad LA, Huang M, Netland PA. Inhibition of Tenon's fibroblasts proliferation and enhancement of filtration surgery in rabbits with cytosine arabinoside. J Ocul Pharmacol Ther. 1999;15:41-49.
240. Wong VK, Shapourifar-Tehrani S, Kitada S, et al. Inhibition of rabbit ocular fibroblast proliferation by 5-fluorouracil and cytosine arabinoside. J Ocul Pharmacol. 1991;7:27-39.
241. Lee DA, Lee TC, Cortes AE, et al. Effects of mithramycin, mitomycin, daunorubicin and bleomycin on human subconjunctival fibroblast attachment and proliferation. Invest Ophthalmol Vis Sci. 1990:31:2136-2144.
242. Demailly P, Kretz G. Daunorubicin versus 5-fluorouracil in surgical treatment of primary open angle glaucoma: A prospective study. Int Ophthalmol. 1992;16:367-370.
243. Rabowsky JH, Dukes AJ, Lee DA, et al. The use of bioerodible polymers and daunorubicin in glaucoma filtration surgery. Ophthalmology. 1996;103:800-807.
244. Saika S, Ooshima A, Yamanaka O, et al. In vitro effects of doxorubicin and mitomycin C on human Tenon's capsule fibroblasts. Ophthalmic Res. 1997;29:91-102.
245. Kay JS, Litin BS, Jones MA, et al. Delivery of antifibroblast agents as adjuncts to filtration surgery-Part II: Delivery of 5-fluorouracil and bleomycin in a collagen implant: Pilot study in the rabbit. Ophthalmic Surg. 1986;17:796-801.
246. Sakamoto T, Oshima Y, Sakamoto M, et al. Electroporation and bleomycin in glaucoma-filtering surgery. Invest Ophthalmol Vis Sci. 1997;38:2864-2868.
247. Oshima Y, Sakamoto T, Nakamura T, et al. The comparative benefits of glaucoma filtering surgery with an electric-pulse targeted drug delivery system demonstrated in an animal model. Ophthalmology. 1999;106:1140-1146.
248. Kirwan JF, Constable PH, Murdoch IE, et al. Beta irradiation: New uses for an old treatment: A review. Eye. 2003;17:207-215.
249. Friedman SM, Munoz B, West SK, et al. The effect of beta irradiation on normal rabbit conjunctiva and fibroblasts in culture. Invest Ophthalmol Vis Sci. 1986;27(suppl):212.
250. Luce EA. The irradiated wound. Surg Clin North Am. 1984;64:821-829.
251. Miller MH, Grierson I, Unger WG, et al. The effect of topical dexamethasone and preoperative beta irradiation on a model of glaucoma fistulizing surgery in the rabbit. Ophthalmic Surg. 1990;21:44-54.
252. Constable PH, Crowston JG, Occleston NL, et al. Long term growth arrest of human Tenon's fibroblasts following single applications of beta radiation. Br J Ophthalmol. 1998;82:448-452.
253. Lai JS, Poon AS, Tham CC, et al. Trabeculectomy with beta radiation: Long-term follow-up. Ophthalmology. 2003;110:1822-1826.
254. Rehman SU, Amoaku WM, Doran RM, et al. Randomized controlled clinical trial of beta irradiation as an adjunct to trabeculectomy in open-angle glaucoma. Ophthalmology. 2002;109:302-306.
255. Barnes RM, Mora JS, Best SJ. Beta radiation as an adjunct to low-risk trabeculectomy. Clin Experiment Ophthalmol. 2000;28:259-262.
256. Diestelhorst M, Grisanti S. Photodynamic therapy to control fibrosis in human glaucomatous eyes after trabeculectomy: A clinical pilot study. Arch Ophthalmol. 2002;120:130-134.
257. Jordan JF, Diestelhorst M, Grisanti S, et al. Photodynamic modulation of wound healing in glaucoma filtration surgery. Br J Ophthalmol. 2003;87:870-875.
258. Longo R, Sarmiento R, Fanelli M, et al. Anti-angiogenic therapy: Rationale, challenges and clinical studies. Angiogenesis. 2002;5:237-256.
259. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA. 1995;92:10457-10461.
260. Paikal D, Zhang G, Cheng QI, et al. The effect of integrin antibodies on the attachment and proliferation of human Tenon's capsule fibroblasts. Exp Eye Res. 2000;70:393-400.
261. Avila M, Ortiz G, LozanoJM, et al. GGRGDSPCA peptide: A new antiscarring agent on glaucoma filtration surgery. Ophthalmic Surg Lasers. 2001;32:134-139.
262. Hammes HP, Brownlee M, Jonczyk A, et al. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nat Med. 1996;2:529-533.
263. Kim JH, Kim JC, Shin SH, et al. The inhibitory effects of recombinant plasminogen kringle 1-3 on the neovascularization of rabbit cornea induced by angiogenin, bFGF, and VEGF. Exp Mol Med. 1999;31:203-209.
264. Wong J, Wang N, Miller JW, et al. Modulation of human fibroblast activity by selected angiogenesis inhibitors. Exp Eye Res. 1994;58:439-451.
265. Fourman S. Effects of aminoproprionitrile on glaucoma filter blebs in rabbits. Ophthalmic Surg. 1988;19:649-652.
266. McGuigan L, Mason RP, Sanchez R, et al. D-penicillamine and beta-aminopropio-nitrile effects on experimental filtering surgery. Invest Ophthalmol Vis Sci. 1987;28:1625-1629.
267. Moorhead LC, Smith J, Stewart R, et al. Effects of beta-aminopropionitrile after glaucoma filtration surgery: Pilot human trial. Ann Ophthalmol. 1987;19:223-225.
268. McGuigan LJ, Quigley HA, Lutty G, et al. The effects of D-penicillamine and daunorubicin on conjunctival fibroblast proliferation and collagen synthesis. Invest Ophthalmol Vis Sci. 1988;29:112-118.
269. McGuigan LJ, Cook DJ, Yablonski ME. Dexamethasone, D-penicillamine, and glaucoma filter surgery in rabbits. Invest Ophthalmol Vis Sci. 1986;27:1755-1757.
270. Schlotzer-Schrehardt U, Lommatzsch J, Kuchle M, et al. Matrix metalloproteinases and their inhibitors in aqueous humor of patients with pseudoexfoliation syndrome/glaucoma and primary open-angle glaucoma. Invest Ophthalmol Vis Sci. 2003;44:1117-1125.
271. Agapova OA, Ricard CS, Salvador-Silva M, et al. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human optic nerve head astrocytes. Glia. 2001;33:205-216.
272. Di Girolamo N, McCluskey P, Lloyd A, et al. Expression of MMPs and TIMPs in human pterygia and cultured pterygium epithelial cells. Invest Ophthalmol Vis Sci. 2000;41:671-679.
273. Li DQ, Lee SB, Gunja-Smith Z, et al. Overexpression of collagenase (MMP-1) and stromelysin (MMP-3) by pterygium head fibroblasts. Arch Ophthalmol. 2001;119:71-80.
274. Black JL, Burgess JK, Johnson PR. Airway smooth muscle-its relationship to the extracellular matrix. Respir Physiol Neurobiol. 2003;137:339-346.
275. Benjamin IJ. Matrix metalloproteinases: From biology to therapeutic strategies in cardiovascular disease. J Investig Med. 2001;49:381-397.
276. Muller D, Roessner A, Rocken C. Distribution pattern of matrix metalloproteinases 1, 2, 3, and 9, tissue inhibitors of matrix metalloproteinases 1 and 2, and alpha 2-macroglobulin in cases of generalized AA- and AL amyloidosis. Virchows Arch. 2000;437:521-527.
277. Salminen HJ, Saamanen AM, Vankemmelbeke MN, et al. Differential expression patterns of matrix metalloproteinases and their inhibitors during development of osteoarthritis in a transgenic mouse model. Ann Rheum Dis. 2002;61:591-597.
278. Kahari VM, Saarialho-Kere U. Matrix metalloproteinases in skin. Exp Dermatol. 1997;6:199-213.
279. Woessner JF Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991;5:2145-2154.
280. Mauch C, Krieg T, Bauer EA. Role of the extracellular matrix in the degradation of connective tissue. Arch Dermatol Res. 1994;287:107-114.
281. Daniels JT, Cambrey AD, Occleston NL, et al. Matrix metalloproteinase inhibition modulates fibroblast-mediated matrix contraction and collagen production in vitro. Invest Ophthalmol Vis Sci. 2003;44:1104-1110.
282. Sheridan CM, Occleston NL, Hiscott P, et al. Matrix metalloproteinases: A role in the contraction of vitreo-retinal scar tissue. Am J Pathol. 2001;159:1555-1566.
283. Scott KA, Wood EJ, Karran EH. A matrix metalloproteinase inhibitor which prevents fibroblast-mediated collagen lattice contraction. FEBS Lett. 1998;441:137-140.
284. Wong TT, Mead AL, Khaw PT. Matrix metalloproteinase inhibition modulates postoperative scarring after experimental glaucoma filtration surgery. Invest Ophthalmol Vis Sci. 2003;44:1097-1103.
285. Pasquale LR, Dorman-Pease ME, Lutty GA, et al. Immunolocalization of TGF-beta 1, TGF-beta 2, and TGF-beta 3 in the anterior segment of the human eye. Invest Ophthalmol Vis Sci. 1993;34:23-30.
286. Jampel HD, Roche N, Stark WJ, et al. Transforming growth factor-beta in human aqueous humor. Curr Eye Res. 1990;9:963-969.
287. Tripathi RC, Li J, Chan WF, et al. Aqueous humor in glaucomatous eyes contains an increased level of TGF-beta 2. Exp Eye Res. 1994;59:723-727.
288. Inatani M, Tanihara H, Katsuta H, et al. Transforming growth factor-beta 2 levels in aqueous humor of glaucomatous eyes. Graefes Arch Clin Exp Ophthalmol. 2001;239:109-113.
289. Ochiai Y, Ochiai H. Higher concentration of transforming growth factor-beta in aqueous humor of glaucomatous eyes and diabetic eyes. Jpn J Ophthalmol. 2002;46:249-253.
290. Kay EP, Lee HK, Park KS, et al. Indirect mitogenic effect of transforming growth factor-beta on cell proliferation of subconjunctival fibroblasts. Invest Ophthalmol Vis Sci. 1998;39:481-486.
291. Denk PO, Hoppe J, Hoppe V, et al. Effect of growth factors on the activation of human Tenon's capsule fibroblasts. Curr Eye Res. 2003;27:35-44.
292. Khaw PT, Occleston NL, Schultz G, et al. Activation and suppression of fibroblast function. Eye. 1994;8:188-195.
293. Cordeiro MF, Gay JA, Khaw PT. Human anti-transforming growth factor-beta 2 antibody: A new glaucoma anti-scarring agent. Invest Ophthalmol Vis Sci. 1999;40:2225-2234.
294. Mead AL, Wong TT, Cordeiro MF, et al. Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Invest Ophthalmol Vis Sci. 2003;44:3394-3401.
295. Siriwardena D, Khaw PT, King AJ, et al. Human antitransforming growth factor beta(2) monoclonal antibody-a new modulator of wound healing in trabeculectomy: A randomized placebo controlled clinical study. Ophthalmology. 2002;109:427-431.
296. Cordeiro MF, Mead A, Ali RR, et al. Novel antisense oligonucleotides targeting TGF-beta inhibit in vivo scarring and improve surgical outcome. Gene Ther. 2003;10:59-71.
297. Teng J, Fukuda N, Hu WY, et al. DNA-RNA chimeric hammerhead ribozyme to transforming growth factor-beta(1) mRNA inhibits the exaggerated growth of vascular smooth muscle cells from spontaneously hypertensive rats. Cardiovasc Res. 2000;48:138-147.
298. Su JZ, Fukuda N, Hu WY, et al. Ribozyme to human TGF-beta1 mRNA inhibits the proliferation of human vascular smooth muscle cells. Biochem Biophys Res Commun. 2000;278:401-407.
299. Kim H, Peterson TG, Barnes S, Mechanisms of action of the soy isoflavone genistein: Emerging role for its effects via transforming growth factor beta signaling pathways. Am J Clin Nutr. 1998;68(6 suppl):1418S-1425S.
300. Bonnet F, Cao Z, Cooper ME, et al. Tranilast attenuates vascular hypertrophy, matrix accumulation and growth factor overexpression in experimental diabetes. Diabetes Metab. 2003;29:386-392.
301. Ochiai H, Ochiai Y, Chihara E. Tranilast inhibits TGF-A1 secretion without affecting its mRNA levels in conjunctival cells. Kobe J Med Sci. 2001;47:203-209.
302. Yasukawa T, Kimura H, Dong J, et al. Effect of tranilast on proliferation, collagen gel contraction, and transforming growth factor beta secretion of retinal pigment epithelial cells and fibroblasts. Ophthalmic Res. 2002;34:206-212.
303. Oshima T, Kurosaka D, Kato K, et al. Tranilast inhibits cell proliferation and collagen synthesis by rabbit corneal and Tenon's capsule fibroblasts. Curr Eye Res. 2000;20:283-286.
304. Tani E, Katakami C, Negi A. Effects of various eye drops on corneal wound healing after superficial keratectomy in rabbits. Jpn J Ophthalmol. 2002;46:488-495.
305. Chihara E, Dong J, Ochiai H, et al. Effects of tranilast on filtering blebs: A pilot study. J Glaucoma. 2002;11:127-133.
306. Mietz H, Chevez-Barrios P, Lieberman MW. A mouse model to study the wound healing response following filtration surgery. Graefes Arch Clin Exp Ophthalmol. 1998;236:467-475.
307. Akman A, Bilezikci B, Kucukerdonmez C, et al. Suramin modulates wound healing of rabbit conjunctiva after trabeculectomy: Comparison with mitomycin C. Curr Eye Res. 2003;26:37-43.
308. Mietz H, Chevez-Barrios P, Feldman RM, et al. Suramin inhibits wound healing following filtering procedures for glaucoma. Br J Ophthalmol. 1998;82:816-820.
309. Mietz H, Krieglstein GK. Suramin to enhance glaucoma filtering procedures: A clinical comparison with mitomycin. Ophthalmic Surg Lasers. 2001;32:358-369.
310. Chang L, Siriwardena D, Wilkins MR, et al. In vivo production of interferon beta by human Tenon's fibroblasts; A possible mediator for the development of chronic conjunctival inflammation. Br J Ophthalmol. 2002;86:611-615.
311. Granstein RD, Rook A, Flotte TJ, et al. A controlled trial of intralesional recombinant interferon-gamma in the treatment of keloidal scarring. Clinical and histologic findings. Arch Dermatol. 1990;126:1295-1302.
312. Berman B, Duncan MR. Short-term keloid treatment in vivo with human interferon alfa-2b results in a selective and persistent normalization of keloidal fibroblast collagen, glycosaminoglycan, and collagenase production in vitro. J Am Acad Dermatol. 1989;21:694-702.
313. Wong TW, Chiu HC, Yip KM. Intralesional interferon alpha-2b has no effect in the treatment of keloids. Br J Dermatol. 1994;130:683-685.
314. Larrabee WF Jr. Keloid excision and recurrence prophylaxis via interdermal interferon-gamma injections. Laryngoscope. 1997;107:1284.
315. al-Khawajah MM. Failure of interferon-alpha 2b in the treatment of mature keloids. Int J Dermatol. 1996;35:515-517.
316. Gillies MC, Brooks AM, Young S, et al. A randomized phase II trial of interferon-alpha2b versus 5-fluorouracil after trabeculectomy. Aust N Z J Ophthalmol. 1999;27:37-44.
317. Palmer ML, Hyndiuk RA. Toxicology of corticosteroids and other anti-inflammatory agents. In: Principles and Practice of Ophthalmology. 2nd ed. Philadelphia, PA: W.B. Saunders; 2000.
318. Cristofanilli M, Pescosolido N, Risuleo G, et al. A murine cell culture model for post-trabeculectomy anfibrotic treatment: Induction of apoptosis by cyclosporine. Acta Ophthalmol Scand. 2001;79:309-312.
319. Nuzzi R, Cerruti A, Finazzo C. Cyclosporine C: A study of wound-healing modulation after trabeculectomy in rabbit. Acta Ophthalmol Scand Suppl. 1998;227:48-49.
320. Park KH, Kim DM, Youn DH. Topical cyclosporine and glaucoma drainage implant surgery in rabbits. Ophthalmic Surg Lasers. 1996;27:452-458.
321. Turacli ME, Gunduz K, Aktan G, et al. Topical cyclosporine as a possible new antimetabolite in trabeculectomy. Ophthalmic Surg Lasers. 1996;27:438-444.
322. Turacli E, Gunduz K, Aktan G, et al. A comparative clinical trial of mitomycin C and cyclosporine A in trabeculectomy. Eur J Ophthalmol. 1996;6:398-401.
323. Gartel AL, Serfas MS, Tyner AL. p21: Negative regulator of the cell cycle. Proc Soc Exp Biol Med. 1996;213:138-149.
324. Perkins TW, Faha B, Ni M, et al. Adenovirus-mediated gene therapy using human p21WAF-1/Cip-1 to prevent wound healing in a rabbit model of glaucoma filtration surgery. Arch Ophthalmol. 2002;120:941-949.
325. Faha BA, Heatley G, Kiland J, et al. Antiproliferative p21WAF-1/Cip-1 gene therapy and trabeculectomy controls IOP and reduces optic nerve damage in a primate model of glaucoma. Invest Ophthalmol Vis Sci. 2002; abstract 1940.
326. Wen SF, Chen Z, Nery J, et al. Characterization of adenovirus p21 gene transfer, biodistribution, and immune response after local ocular delivery in New Zealand white rabbits. Exp Eye Res. 2003;77:355-365.
327. Fuller JR, Bevin TH, Molteno AC, et al. Anti-inflammatory fibrosis suppression in threatened trabeculectomy bleb failure produces good long term control of intraocular pressure without risk of sight threatening complications. Br J Ophthalmol. 2002;12:1352-1354.